Group 1 - The cosmetics sector experienced a rise of 1.11% on January 20, with Shanghai Jahwa leading the gains [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] - Key stocks in the cosmetics sector showed varied performance, with Shanghai Jahwa closing at 23.92, up 3.55%, and Qingdao Kingking at 8.34, up 2.96% [1] Group 2 - The cosmetics sector saw a net inflow of 30.3 million yuan from institutional investors, while retail investors experienced a net outflow of 54.5 million yuan [2] - Notable individual stock performances included Shanghai Jahwa with a net inflow of 20.5 million yuan from institutional investors, and Qingdao Kingking with a net inflow of 23.3 million yuan [3] - The overall market sentiment reflected a mixed response, with some stocks like Banlaya experiencing significant net outflows from both institutional and retail investors [3]

Core Viewpoint - The company is actively exploring the application of AI and other cutting-edge technologies in the field of skin health, emphasizing its commitment to technology-driven development [1] Group 1: AI Application in Business - The company has initiated practices involving AI in certain business segments, such as providing AI-assisted personalized skincare solutions through its professional acne treatment brand "Beifuting" [1] - The collaboration with YaoSu Technology aims to explore new intelligent detection pathways, including "AI + organ-on-chip" technology [1] Group 2: Future Directions - The application of AI technology is identified as a key direction for the company's development, with ongoing efforts to advance related explorations [1] - Specific details regarding collaborative scenarios, quantifiable outcomes, and patent strategies are considered internal R&D and operational information [1]

Core Viewpoint - The company is actively exploring the application of AI and other cutting-edge technologies in the field of skin health, emphasizing its commitment to technology-driven development [1] Group 1: AI Application in Business - The company has initiated practices involving AI in certain business segments, such as providing AI-assisted personalized skincare solutions through its professional acne treatment brand "Beifuting" [1] - The collaboration with YaoSu Technology aims to explore new intelligent detection paths, including "AI + organ-on-chip" technology [1] Group 2: Future Directions - The application of AI technology is identified as a key direction for the company's development, with ongoing efforts to advance related explorations [1] - Specific details regarding collaborative scenarios, quantifiable outcomes, and patent strategies are considered internal R&D and operational information [1]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights the competitive advantage of Qian Dama through its "community small store + daily clearance mechanism + warehouse and cold chain" model, which enhances supply stability and operational efficiency [3][24][35] - The report emphasizes the importance of emotional consumption themes and identifies high-quality companies in high-growth sectors, recommending specific companies across various segments [6][37] Summary by Sections Industry Overview - The retail and social service indices reported a decline of 1.47% and an increase of 1.53% respectively during the week of January 12-16, 2026 [5][13] - The internet e-commerce sector showed the highest growth, with a year-to-date increase of 11.18% [16][19] Company Highlights - Qian Dama has submitted its IPO application to the Hong Kong Stock Exchange, focusing on fresh food retail in the South China market, with a GMV of 9.8 billion yuan in 2024, significantly outperforming its competitors [24][25] - The company operates 2,983 stores, with 2,898 being franchise stores, contributing over 90% of its revenue [25][31] - The report recommends several companies based on their performance and market positioning, including: - Chaohongji, expected to achieve a net profit of 436-533 million yuan in 2025, driven by brand upgrades and channel expansion [39][43] - Meilitiantian Medical Health, projected to see a revenue increase of 28.2% in FY2025H1 [39] - Zhou Dafu, focusing on product structure optimization and store upgrades [39] Investment Themes - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending Chaohongji and Laopu Gold [6][37] - Investment Theme 2: Emphasize retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket and Aiyingshi [6][37] - Investment Theme 3: Highlight domestic beauty brands that meet emotional value and safety innovation, recommending Maogeping and Pola [6][37] - Investment Theme 4: Focus on differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending Meilitiantian Medical Health and Aimeike [6][37]

Group 1 - The core viewpoint of the news is that Betaini has made significant progress in the upstream medical beauty industry chain with the approval of a new product, marking a breakthrough in the field [1] - The product, an injectable poly-L-lactic acid filler, is the first globally approved for use in the temporal region, and it is also the first approval in China for this specific application [1] - The product utilizes proprietary MEDBIOMA poly-L-lactic acid material and EvolaONE microsphere technology developed by Chengdu Yizhen, a subsidiary of Yizheng (Suzhou) Biotechnology Co., Ltd., in which Betaini holds a 15.73% stake [1] Group 2 - Analysts indicate that the approval of the core product of the invested enterprise signifies an important step for Betaini in building a skin health ecosystem through strategic investments and collaborations in the upstream biomaterials sector [2] - By strategically entering the upstream biomaterials field, Betaini is constructing a more layered and technically deep value chain for its long-term development in the skin health sector [2]

Core Insights - Betaini Group has made significant progress in the upstream medical beauty industry chain with the approval of a new product by its strategic investment, Yizheng (Suzhou) Biotechnology Co., Ltd, which holds 15.73% of its shares [1][4] - The approved product, an injectable poly-L-lactic acid filler, is the first of its kind globally to be approved for use in the temporal region, marking a milestone for the company and the industry in China [1][4] Group 1 - The product received a Class III medical device registration certificate from the National Medical Products Administration (NMPA), indicating its compliance with regulatory standards [1] - The filler utilizes proprietary MEDBIOMA® poly-L-lactic acid material and EvolaONE® microsphere technology developed by the company's core team [1][4] Group 2 - Chengdu Yizhen, founded by a team of scientists led by Dr. Zhang Xiaojin, focuses on the clinical transformation of absorbable biomaterials and has previously launched other Class III medical devices [4] - The approval of this core product signifies a strategic move by Betaini to enhance its value chain in skin health through investment and collaboration in the upstream biomaterials sector [4]

Market Overview - The cosmetics sector experienced a decline of 0.36% on January 15, with Shuiyang Co. leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Jinsheng New Material (300849) saw a significant increase of 13.17%, closing at 18.48 with a trading volume of 117,000 shares and a turnover of 209 million yuan [1] - Qingdao Kingway (002094) increased by 2.06%, closing at 8.42 with a trading volume of 1,113,500 shares [1] - Lafang Home (603630) rose by 1.76%, closing at 24.27 with a trading volume of 137,300 shares [1] - Other notable performances include Fulejia (301371) up 0.73%, Marubi Biological (603983) up 0.70%, and Betaini (300957) up 0.32% [1] Capital Flow Analysis - The cosmetics sector saw a net outflow of 11.86 million yuan from institutional investors and 53.27 million yuan from retail investors, while retail investors had a net inflow of 65.13 million yuan [2] - The capital flow for individual stocks indicates that Lafang Home had a net inflow of 77.73 million yuan from institutional investors, while Betaini had a net inflow of 14.81 million yuan [3] - Conversely, Shuiyang Co. experienced a net outflow of 5.39 million yuan from institutional investors [2][3]

Group 1 - The core viewpoint of the article highlights that Betaini is actively engaging in industrial investment and strategic layout through its subsidiary, Hainan Betaini Investment Co., Ltd [2] - The investment activities are closely aligned with the company's strategic direction focused on skin health ecology [2] - The investment scope includes over ten companies, such as Yuejiang (Guangzhou) Investment Co., Ltd. and Changsha Yujian Future Technology Co., Ltd [2]

Group 1 - The core viewpoint of the article is that Beitaini is actively engaging in investment activities that align with its strategic direction in skin health ecology [1] - Hainan Beitaini Investment Co., Ltd. is identified as a key platform for the company's industrial investment and layout [1] - The investment activities encompass over ten companies, including Yuejiang (Guangzhou) Investment Co., Ltd. and Changsha Yujian Future Technology Co., Ltd. [1]

Group 1 - The core viewpoint of the article is that Hainan Beitaini Investment Co., Ltd. is a significant platform for the company's industrial investment and strategic layout, focusing on skin health ecology [2] - The investment activities are closely aligned with the company's strategic direction in skin health, indicating a targeted approach to investment [2] - Hainan Beitaini has invested in over ten companies, including Yuejiang (Guangzhou) Investment Co., Ltd. and Changsha Yujian Future Technology Co., Ltd. [2]